You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 19, 2024

CLINICAL TRIALS PROFILE FOR BETRIXABAN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Betrixaban

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00375609 ↗ Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT) Completed Portola Pharmaceuticals Phase 2 2006-05-01 Randomized study of PRT054021 40 mg and 15 mg bid vs. enoxaparin 30 mg q12h for the prophylaxis of venous thromboembolic events after unilateral knee replacement surgery.
NCT00742859 ↗ Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin Completed Portola Pharmaceuticals Phase 2 2008-10-01 Prevention of stroke in patients with atrial fibrillation (AF). Hypothesis: In patients with non-valvular AF, orally administered betrixaban will provide similar or better efficacy and safety than warfarin and it will offer the advantage of not requiring dose adjustments due to international normalized ratios (INRs) outside the target range of 2.0 to 3.0 and a more consistent level of anticoagulation over time.
NCT00999336 ↗ A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment Completed Merck Sharp & Dohme Corp. Phase 1 2009-07-01 The purpose of the study is to compare the pharmacokinetics, pharmacodynamics, and tolerability of betrixaban in patients with mild, moderate, and severe renal impairment to healthy volunteers.
NCT00999336 ↗ A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment Completed Portola Pharmaceuticals Phase 1 2009-07-01 The purpose of the study is to compare the pharmacokinetics, pharmacodynamics, and tolerability of betrixaban in patients with mild, moderate, and severe renal impairment to healthy volunteers.
NCT01229254 ↗ Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter Completed Portola Pharmaceuticals Phase 2 2010-09-01 The primary purpose of this study is to optimize drug exposure in the target population.
NCT01229254 ↗ Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter Completed Merck Sharp & Dohme Corp. Phase 2 2010-09-01 The primary purpose of this study is to optimize drug exposure in the target population.
NCT01583218 ↗ Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study) Completed Portola Pharmaceuticals Phase 3 2012-03-01 The purpose of this study is to evaluate whether extended prophylaxis with oral betrixaban can prevent blood clots in the leg and lung that sometime occur in patients hospitalized for an acute medical illness and to compare these results with standard of care enoxaparin. The safety of betrixaban will also be studied.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Betrixaban

Condition Name

Condition Name for Betrixaban
Intervention Trials
Atrial Fibrillation 2
Atrial Flutter 1
Bleeding 1
Healthy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Betrixaban
Intervention Trials
Atrial Fibrillation 2
Thromboembolism 2
Liver Diseases 1
Venous Thromboembolism 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Betrixaban

Trials by Country

Trials by Country for Betrixaban
Location Trials
United States 47
Canada 7
Spain 6
Australia 4
South Africa 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Betrixaban
Location Trials
California 4
Florida 3
Maryland 2
Illinois 2
Colorado 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Betrixaban

Clinical Trial Phase

Clinical Trial Phase for Betrixaban
Clinical Trial Phase Trials
Phase 3 1
Phase 2 4
Phase 1 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Betrixaban
Clinical Trial Phase Trials
Completed 9
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Betrixaban

Sponsor Name

Sponsor Name for Betrixaban
Sponsor Trials
Portola Pharmaceuticals 11
Merck Sharp & Dohme Corp. 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Betrixaban
Sponsor Trials
Industry 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.